ISRCTN11623624 https://doi.org/10.1186/ISRCTN11623624

Ginger (Zingiber officinale) as anti-emetic prophylaxis for chemotherapy-induced nausea and vomiting

Submission date 30/09/2005	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol
Registration date 30/09/2005	**Overall study status** Completed	[ ] Statistical analysis plan [ ] Results
Last Edited 31/03/2020	**Condition category** Signs and Symptoms	[ ] Individual participant data [ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Ms Kerry Guile

Contact details
Oncology Dept
Jenner Wing Level 2
St George's Hospital
Blackshaw Road
Tooting
London
United Kingdom
SW17 0QT

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0236151198

Study information

Scientific Title
Ginger (Zingiber officinale) as anti-emetic prophylaxis for chemotherapy-induced nausea and vomiting

Study objectives
To establish the antiemetic efficacy of ginger (Zingiber officinale) in addition to standard antiemetic therapy for highly emetogenic cancer chemotherapy.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled open-label trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Signs and Symptoms: Nausea and vomiting

Interventions
A single supply of commercially available ginger capsules will be purchased. Patients in the study group will receive 550mg orally 3x a day for 5 days. 1st dose will be administered 1 hour prior to the first dose of chemotherapy. Trial medication will be used during the first cycle of chemotherapy only.

Study protocol: The study will recruit patients receiving FEC chemotherapy or any regimen containing cisplatin at 50mg/m2 or more in a single dose. Patients will be randomly and evenly allocated into 2 groups.
Group 1 - 59 patients receiving standard antiemetic therapy.
Group 2 - 59 patients receiving standard therapy plus ginger. Randomisation will be performed by the Clinical Trials Support Unit, Institute of Cancer Research.

Regimens: The chemotherapy unit at St George's Hospital has had a formal antiemetic policy in operation since 1998. Patients receiving FEC or cisplatin-based chemotherapy are routinely offered 'Level 4' antiemetic prophylaxis.

Schedule of clinical activity: Patients will be given a diary card to record nausea and episodes of vomiting for 5 days following administration of chemotherapy. Investigators will independently record episodes of nausea or vomiting on the Case Report Form. The use of salvage antiemetics will also be noted. Both nausea and vomiting will be graded according to the NCI common toxicity criteria.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Ginger (Zingiber officinale)

Primary outcome measure
Total antiemetic control (no nausea or vomiting during the study period)

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/05/2003

Completion date
01/05/2005

Eligibility

Key inclusion criteria
118 cancer patients

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
118

Key exclusion criteria

1. Any prior chemotherapy
2. Anticipatory nausea/vomiting
3. Concurrent use of products containing ginger or ginger preparations
4. Concurrent use of any other experimental drugs
5. Clinical or radiological evidence of cerebral metastases
6. Clinical or radiological evidence of intestinal obstruction; any profound metabolic disturbance liable to cause nausea and vomiting (hypercalcaemia, diabetic ketoacidosis etc)
7. Any history of hypersensitivity to ginger
8. Any condition precluding the use of standard antiemetic therapy

Date of first enrolment
01/05/2003

Date of final enrolment
01/05/2005

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
St George's Hospital
London
United Kingdom
SW17 0QT

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

Sponsor type
Government

Website
http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
St George's Healthcare NHS Trust (UK), NHS R&D Support Funding

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration